Patients, your care and safety are our top priorities! We encourage you to follow CDC guidelines to self- quarantine if you are experiencing symptoms
consistent with COVID-19. Please do not hesitate to call us to assess whether to reschedule your appointment. Please call 716-631-2500 .

Nuclear Medicine – Bone


Nuclear Medicine studies are performed at the 55 Spindrift Drive office in Williamsville by technologists that are NMTCB and/or ARRT certified in Nuclear Medicine. Windsong Radiology Group has two GE Millennium MG dual head SPECT (Single Photon Emission Computerized Tomography) nuclear cameras. In addition to routine nuclear imaging, we perform several specialized nuclear procedures. These include thyroid therapy for hyperthyroidism and Quadramet® therapy for pain management in patients with bone metastases, and radioimmunotherapy for treatment of non-Hodgkin’s lymphoma. Windsong Radiology Group is also offering a new FDA approved treatment for prostate cancer. Xofigo® (Radium 223 dichloride) is a new therapy used to treat prostate cancer that is resistant to other medical and surgical treatments that seek to lower testosterone levels in patients whose disease has spread to the bones. To learn more, click here. Somatostatin-type receptor binding peptide radiopharmaceuticals are approved for the detection of neuroendocrine tumors. Ostreoscan is utilized for the rapid detection and localization of neuroendocrine tumors, primary or metastatic, which are often missed by conventional imaging procedures. ProstaScint® Imaging is one of the new offerings in nuclear medicine. The monoclonal antibody is used in the detection of recurrent prostate cancer with lymph node involvement. CT images of the pelvis are fused with the nuclear images to precisely pinpoint any areas that are suspicious for cancer.

Additionally, Windsong is now offering Ga 68, NETSPOTTM , used to localize endocrine tumors for

  • Staging
  • Restaging
  • Improved lesion detection compared to Octreoscan
  • Not for diagnosing

After radiolabeling with GA 68, NETSPOTTM is a radioactive diagnostic agent indicated for use with PET for localization of somatostatin receptor positive neuroendocrine tumor in adults and pediatric patients. Simply put, the Dotatate attaches to the receptor.

NIH research shows that Ga 68 dotatate PET can change patient management in nearly 71% of patients with neuroendocrine tumors by providing more accurate and clinically relevant information.


Studies Offered

Bone Marrow Scans Lung Scans (ventilation or perfusion)
Bone Scans Lymphosintigraphy (melanoma)
Breast Lymphoscintography Meckel’s Diverticulum
Cardiac First Pass Study Ostreoscan
Cardiac Gated-Blood Pool Parathyroid
Cisternograms ProstaScint®
Gallium Scan Quadramet®
Gallium Scan- Tumor/Infection Renal Scan (Lasix/captopril)
Gastric Emptying Salivary Gland
Hemangioma-Hepatic Blood Pool Tc99 White Cell Label (HMPAO)
Hepatobiliary (HIDA) Techetium Thyroid Imaging
I-131 Whole Body Scan Testicular Flow & Scan
Liver/Spleen Scan Thyroid Uptake and Scan
Lung Quantitative Scan WBC Localization